NCT01576029 - Continued Treatment With Docetaxel Versus Switch to Cabazitaxel After Minor Prostate Specific Antigen Response to Docetaxel in Patients With Castration-Resistant Metastatic Prostate Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

August 31, 2012

Primary Completion Date

December 31, 2013

Study Completion Date

December 31, 2013

Conditions

Prostatic Neoplasms

Interventions

DRUG

CABAZITAXEL (XRP6258)

Pharmaceutical form: solution Route of administration: intravenous

DRUG

DOCETAXEL (XRP6976)

Pharmaceutical form: solution Route of administration: intravenous

Trial Locations (8)

Investigational Site Number 004, Barretos

Investigational Site Number 008, Brasília

Investigational Site Number 009, Londrina

Investigational Site Number 003, Mogi das Cruzes

Investigational Site Number 005, Porto Alegre

Investigational Site Number 006, Rio de Janeiro

Investigational Site Number 001, Rio de Janeiro

Investigational Site Number 007, São Paulo